Prostate cancer prevention: What do we know now, and when will we know more?

Ian M Thompson, Joseph Basler, Deborah Hensley, Dendra Von Merveldt, Carol A. Jenkins, Betsy Higgins, Robin Leach, Dean Troyer, Brad Pollock

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Prostate cancer prevention is now one of the most aggressively investigated areas of urologic oncology, with > 30,000 men currently participating in clinical trials in the United States alone. The Prostate Cancer Prevention Trial will complete end-of-study prostate biopsies in May 2004, and the Selenium and Vitamin E Cancer Prevention Trial is rapidly reaching its accrual goal 1-2 years ahead of schedule. These 2 studies will give definitive answers regarding 3 of the most important potential preventive interventions: finasteride, vitamin E, and selenium. Many phase II and biomarker-modulation studies are also ongoing, testing a host of other interventions. It is hoped that, within a short period of time, the clinician will be provided with strategies to reduce the risk of the disease.

Original languageEnglish (US)
Pages (from-to)215-220
Number of pages6
JournalClinical Prostate Cancer
Issue number4
StatePublished - Mar 2003


  • Biomarker
  • Early detection
  • Hormonal agents
  • Selenium
  • Vitamin E

ASJC Scopus subject areas

  • Urology
  • Oncology


Dive into the research topics of 'Prostate cancer prevention: What do we know now, and when will we know more?'. Together they form a unique fingerprint.

Cite this